These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19463066)

  • 1. Pharmacotherapy of multiple sclerosis: the PROOF trial.
    Boster A; Racke MK
    Expert Opin Pharmacother; 2009 Jun; 10(8):1235-7. PubMed ID: 19463066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ
    Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-1a in children with multiple sclerosis is well tolerated.
    Waubant E; Hietpas J; Stewart T; Dyme Z; Herbert J; Lacy J; Miller C; Rensel M; Schwid S; Goodkin D
    Neuropediatrics; 2001 Aug; 32(4):211-3. PubMed ID: 11571702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E
    Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
    Patti F; Pappalardo A; Florio C; Politi G; Fiorilla T; Reggio E; Reggio A
    Acta Neurol Scand; 2006 Apr; 113(4):241-7. PubMed ID: 16542163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.
    Bellomi F; Muto A; Palmieri G; Focaccetti C; Dianzani C; Mattei M; Jaber A; Antonelli G
    New Microbiol; 2007 Jul; 30(3):241-6. PubMed ID: 17802901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.
    Freedman MS; Hughes B; Mikol DD; Bennett R; Cuffel B; Divan V; LaVallee N; Al-Sabbagh A
    Eur Neurol; 2008; 60(1):1-11. PubMed ID: 18437041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis.
    Tenembaum SN; Segura MJ
    Neurology; 2006 Aug; 67(3):511-3. PubMed ID: 16775230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying therapy in multiple sclerosis: update and clinical implications.
    Goodin DS
    Neurology; 2008 Dec; 71(24 Suppl 3):S8-13. PubMed ID: 19064873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
    Giovannoni G; Barbarash O; Casset-Semanaz F; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Mult Scler; 2009 Feb; 15(2):219-28. PubMed ID: 18755819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study.
    Zecca C; Pavelek Z; Přikrylová K; Ghielmetti M; Beeler A; Gobbi C
    Mult Scler Relat Disord; 2019 May; 30():104-109. PubMed ID: 30763907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
    Hernandez-Perez MA;
    Rev Neurol; 2009 May 16-31; 48(10):505-8. PubMed ID: 19434583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients.
    Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
    Eur Neurol; 2009; 61(3):177-82. PubMed ID: 19129705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
    O'Connor P; Kinkel RP; Kremenchutzky M
    Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.